Portal has a new paper published with the latest pain and preference data. The PRECISE II human study demonstrated a preference for needle-free injections. Read the press release and find the full paper here:?https://lnkd.in/ebjHepxA
关于我们
Portal Instruments is a Series C funded medical device company focused on advanced drug delivery and backed by strategic and venture investors. We are developing and commercializing a highly innovative needle-free drug delivery platform technology to transform the administration of medicines and improve the patient experience for those with chronic disease who inject themselves. Portal’s needle-free delivery technology is derived from research at MIT and enables the administration of high viscosity biologic drugs with less discomfort and without the anxiety of handling needles.?Using precise pressure technology, the injection is administered through the skin via a jet the size of a strand of hair, ensuring optimal comfort. Real time tracking and reporting sets a new standard for interactivity between the patient and care teams, monitoring adherence and potentially improving patient outcomes. Come join us on this exciting journey of redefining chronic patient care and comfort. Portal’s platform is in development and not available for sale or use.
- 网站
-
https://www.portalinstruments.com
Portal Instruments的外部链接
- 所属行业
- 医疗设备
- 规模
- 11-50 人
- 总部
- Cambridge，MA
- 类型
- 私人持股
- 创立
- 2012
- 领域
- Chronic Disease、Digital Health、Disease Management Solutions、Medical Device和Drug Delivery Device
地点
-
主要
获取路线
190 Fifth Street
US，MA，Cambridge，02141
Portal Instruments员工
-
Patrick Anquetil
Innovative Drug Delivery CEO @ Portal Instruments | Commercialization
-
Bobby Dyer
Chief Device Architect at Portal Instruments | ART - ENGINEERING - DESIGN
-
Matt Regan
Chief Executive Officer & Board of Directors - Micreos Pharmaceuticals | Independent Board Director, Portal Instruments
-
Lynne Kelley MD, FACS
CEO/CMO Co-Founder
动态
-
On this International Women’s Day, let’s take a moment to celebrate the incredible women of our team at Portal Instruments. Your leadership, resilience, and impact inspire us every day. We deeply appreciate your contributions and the difference you make! #InternationalWomensDay #WomensDay #IWD2025 #drugdelivery
-
Great article by TTP plc highlighting the urgent and massive need for re-usable auto-injectors. "According to one estimate, the number of patients to be treated in the United States is on track to reach 30 million by 2030…the increase in the U.S. alone could equate to 1 billion injections per year.? An additional 1 billion typical single-use AIs discarded after use could equate to 35,000 tonnes or 50,000 cubic meters of waste – and enough devices to circle the globe 3.5 times!?" #DrugDelivery #Innovation #PRIMENexus #Sustainability
-
Portal Instruments will be presenting? @LSI USA ‘25, Medtech’s premier partnering event this March. If you’re attending, make sure to connect with Patrick Anquetil who will be in attendance. #LSIAlumni #medtech #healthtech
-
-
This Pfizer sponsored paper highlights the benefits of reusable, electromechanical injectors, including customizable injection parameters, consistent delivery, electronic logs/reminders, and real-time instructions. Evidence suggests improved patient adherence with these devices, and their reusability offers potential environmental advantages over disposable options. #DrugDelivery #Innovation #PRIMENexus #Sustainability
-
The emergence of (GLP-1) drugs has transformed the management of type 2 diabetes and obesity, yet this popularity introduces an environmental challenge with the amount of auto-injector pens requiring disposal. “In the long term, transitioning toward reusable injection pens offers a promising solution. In this model, the pen would be reusable, with only the medication cartridge needing replacement. This shift would significantly reduce the amount of plastic and sharps waste generated by each patient. While reusable injection pens already exist for other medications, pharmaceutical companies could develop GLP-1 formulations compatible with this technology. Though the initial cost of reusable pens may be higher, the long-term savings in waste management and environmental impact would be substantial.” Thani Jambulingam, PhD, Pharmaceutical Commerce #Innovation #DrugDelivery #sustainability #PRIMENexus
-
Take another look at PRIME Nexus – Innovation in Drug Delivery Portal’s proprietary PRIME Nexus injection platform is designed to deliver high-viscosity biologics and other therapeutics with precision and speed. Our reusable auto-injector seamlessly integrates into daily life, offering a sleek, connected, and modern alternative to traditional disposable injectors. By combining style and functionality, PRIME Nexus empowers users with a discreet and convenient solution for their treatment needs. #PRIMENexus #Innovation #DrugDelivery #AutoInjectors #Biologics
-
-
Excited to share Portal Instruments' amazing new sustainable auto-injector!
Unboxing the PRIME Nexus!? Design, innovation, and seamless functionality in a reusable autoinjector. #PRIMENexus #Innovation #AutoInjectors #FormAndFunction
-
-
Unboxing the PRIME Nexus!? Design, innovation, and seamless functionality in a reusable autoinjector. #PRIMENexus #Innovation #AutoInjectors #FormAndFunction
-